|
|
Fiskartorpsvagen 15 A-D
Stockholm, 114 33 Sweden
phone:+46 (0)8 786 0900
fax:+46 (0)8 786 0911
|
|
| Symbol |
Private |
| Founded |
0 |
| Employees |
|
|
|
| www.neuronova.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Therapeutic Neurogenesis for Treatment of Neurodegenerative Diseases |
|
| Management |
| Ulf Ljungberg, PhD, President and Chief Executive Officer; Anders Haegerstrand, MD, PhD, Vice President and Chief Scientific Officer; Henrik Resmark, MSc, Chief Financial Officer; Kerstin M Genetay, PhD, Senior Project and Patent Manager; Lilian Wikstr�m, PhD, Head of Research; Markus Jerling, MD, PhD - Chief Medical Officer |
| |
|
|
| |
|
| Keywords |
| Neurology, Diagnostics. Amyotrophic Lateral Sclerosis (ALS), Parkinson's Disease, Drug Discovery |
|
|
|
| Description |
|
NeuroNova is engaged in the discovery and the development of drugs that promote neurogenesis, the formation of new neurons, for the treatment of diseases of the central nervous system (CNS), including Parkinson's disease, Alzheimer's disease, Huntington's disease and depression. |
|
| Products / Services |
NeuroNova has two drug candidates in clinical development for Parkinson's disease and ALS.
|
|
| Technology / Differentiation |
| NeuroNova has established proprietary platform technologies, which are assembled into a comprehensive discovery process designed to support the identification of therapeutically relevant drug targets and compounds. The Neurogenesis Qualifier combines in-house expertise in in vitro and in vivo methods with state-of-the-art drug discovery technologies. It is broadly applicable to several CNS therapeutic areas, including Parkinson's disease, Alzheimer's disease, amyotrophic lateral sclerosis (ALS) and Huntington's disease. The technology platform's focus is on data quality and content in order to facilitate scientific decision-making throughout the drug discovery process. The Neurogenesis Qualifier is supported by proprietary in-house databases and tools to efficiently manage volumes of research data, making critical information readily available to our scientists. The Neurogenesis Qualifier can be used to investigate the medicinal potential of novel drug targets and compounds and to identify new CNS uses for existing drugs, thereby providing diversity and balanced risk. |
|
|
| Status |
| In March 2009 NeuroNova received regulatory approval by the Medical Products Agency in Sweden to initiate a first-in-human study with the drug product sNN0031 in patients with Parkinson's disease. |
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members